Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03905473
Other study ID # H-18031231 1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2019
Est. completion date October 10, 2020

Study information

Verified date March 2021
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Danish patients with myasthenia gravis are asked to answer a validated and international questionnaire about physical activity. Also background questions about their disease and comorbidity are asked. To validate the data about physical activity from the questionnaires 69 patients are asked to wear an accelerometer for 7 days to measure activity level.


Description:

Secure digital mails are sent to around1500 patients qua their civil registration number (CPR number) (each resident of Denmark has a permanent unique civil registration number that is provided at birth or immigration to Denmark). The mail contains a link for the software REDCap (© 2018 Vanderbilt University), recommended by Rigshospitalet. REDcap is a secure web application for building and managing online surveys and databases. Patients are, in REDcap, informed about the project, and if interested, asked to sign the included informed content and answer six validated and translated questionnaires.


Recruitment information / eligibility

Status Completed
Enrollment 779
Est. completion date October 10, 2020
Est. primary completion date April 10, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Danish resident. - Alive. - Minimum age 18 years. - Registered in the Danish Patient Register with diagnosis code 70.0 (ICD-10) or 733.09 (ICD 8). - Subscribing E-boks (the Danish system for receiving secure digital emails). Exclusion Criteria: - I fulfilling the inclusion criteria, then no exclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Accelerometer measurements
To validate the questionnaires about physical activity, some patients will be wearing an accelerometer for one week. An accelerometer is a little device worn in a belt around the hip, which can measure intensity of the patient's activity level. The accelerometer is worn 24 hours a day for one week and is only removed when bathing.

Locations

Country Name City State
Denmark Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Gender Are you a woman or a man? 5 seconds
Other Verification of the MG status. Are you diagnosed with MG? (Yes/no/ maybe - still under examination) 5 seconds
Other Age How old are you? (unit: years) 5 seconds
Other Job How is your actually job status? (working fulltime/ working part time, student, retired, out of work, early retiree, sick leave). 5 seconds
Other Smoking Are you a smoker? (Never, ex-smoker, daily smoker, smoker but not every day, using e-cigarettes, using nicotine products) 5 seconds
Other Comorbidity Are you suffering from any of these conditions? (depression, any other psychiatric disorder, any auto-immune disease, chronic obstructive pulmonary disease, any cardiac diseases, chronic fatigue, sleep apnoea) 5 seconds
Other How many years diagnosed with MG? Number of years since diagnosis. 5 seconds
Other Symptoms of MG? The patient register symptoms according to the Myasthenia Gravis Foundation of American clinical classification. 5 seconds
Other Treatment for MG? The patient report their pharmacological treatment for MG. 5 seconds
Other Are you receiving immunoglobulin treatment or plasmaphereses? Answer yes/no. 5 seconds
Other Have you had a thymectomy? Answer yes/no. 5 seconds
Other Are you having any of these treatments? The patient answer yes or no to the following treatments: benzodiazepine, antidepressant drugs or betablockers. 5 seconds
Other Are you reguarly seen by a neurologist? Answer yes/no 5 seconds
Other How tall are you? Answer in centimeter 2 seconds
Other How much do you weight? Answer in kilograms 2 seconds
Other Are you living alone? Yes/no 2 seconds
Other Do you live with children? How many? Answer in number of children 2 seconds
Other Was is your highest education level? Short/middle/high education level 2 seconds
Primary Multidimensional Fatigue Inventory (MFI-20) MFI-20 is a self-reported questionnaire that measures fatigue severity. It contains 20 items and consists of five fatigue domains: mental fatigue, reduced motivation, reduced activity, physical fatigue and general fatigue. The response options consist of five check boxes ranging from "Yes, that is true" to "No, that is not true". The scores in each domain range from 4 to 20, with higher scores indicating higher levels of fatigue. A total fatigue score for all five domains is not used. MFI-20 has been used in several clinical and healthy populations. 5 minutes
Secondary The short International Physical Activity Questionnaire (IPAQ) IPAQ short form is used to measure self-reported time spent on physical activity and sedentary behavior. The questionnaire measures four intensity levels of physical activity from none (sedentary) to strenuous physical activity. Patients are asked to report number of hours and minutes per day on the different activity levels. 3 minutes
Secondary Insomnia Severity Index (ISI) ISI measures self-reported sleep quality and disturbances during the previous 2 weeks. The ISI comprises seven items assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item is rated on a scale from 0 - 4 from less to more severe. The total score is the sum of each individual item and can range from 0 to 28 (28= most severe). 3 minutes
Secondary Myasthenia gravis activity of daily living profile (MG-ADL) Impact on daily living is assessed using the MG-ADL. An eight-question survey of symptoms severity, with each response graded from 0 (normal) to 3 (most severe). Questions include ocular, oropharyngeal, respiratory, and extremity functions. Total MG-ADL score ranges from 0 to 24. MG-ADL is also an indirect measurement of disease severity. 10 minutes
Secondary Myasthenia gravis quality of life 15-item score (MG-QoL15) MG -specific quality-of-life instrument is a 15-item questionnaire encompassing physical and psychological domains of MG to assess disease-specific Qol in MG patients. Rating consist of a 5-point scale ranging from 0 ("not at all") to 4 ("very much") as to the degree to which patients agree with the given statement summing up to a total score 0-60 points. 3 minutes
See also
  Status Clinical Trial Phase
Completed NCT05039190 - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients Phase 3
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT01727193 - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Phase 3
Completed NCT00285350 - Mycophenolate Mofetil in Myasthenia Gravis Phase 3
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed NCT05694234 - Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Not yet recruiting NCT05095103 - Immune Profiles in Myasthenia Gravis
Not yet recruiting NCT04965987 - Oxaloacetate in Myasthenia Gravis Phase 1
Completed NCT02066519 - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis N/A
Completed NCT02774239 - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Phase 3
Terminated NCT02102594 - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Phase 2
Completed NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated NCT01828294 - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis Phase 1
Terminated NCT00727194 - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Phase 2
Completed NCT04590716 - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting NCT04837625 - Study of Myasthenic Crisis in China
Not yet recruiting NCT01469858 - Perception and Multisensory Integration in Neurological Patients Using fMRI N/A
Completed NCT05408702 - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed NCT03205306 - Myasthenia Gravis and Psyche